{
  "abstract": "Loss or downregulation of MHC-I is a frequent mechanism of immune evasion in central nervous system (CNS) cancers, partially driven by an immunologically cold microenvironment. In this short commentary, we issue a call to action for exploring therapeutic strategies of MHC-I expression restoration in brain cancers to improve patient outcomes. We discuss several potential strategies, including targeting the immunosuppressive microenvironment, epigenetic modulation, and gene therapy approaches. We argue that effective MHC-I restoration may require a combinatorial approach that simultaneously boosts both antigen processing and presentation and remodels the tumor microenvironment. Overcoming CNS-specific barriers, such as the blood-brain barrier, is critical for success. We propose that combining MHC-I re-expression with immunotherapy, chemotherapy, and radiotherapy could provide new therapeutic windows for CNS malignancies.",
  "abstract_shown": true,
  "affiliations": [
    "Research Center for Translational Medicine, Sirius University of Science and Technology, Sochi, Russia",
    "Altogen Labs, Austin, TX, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Amikishiev Sahil V."
    },
    {
      "affs": [
        0
      ],
      "name": "Kuzmin Dmitry A."
    },
    {
      "affs": [
        1
      ],
      "name": "Ovcharenko Dmitriy"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuzhalin Arseniy E."
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/cnh1e5kt5spzt.bib",
  "cited_by": 0,
  "doi": "10.1515/oncologie-2026-0225",
  "fulltext_url": "https://doi.org/10.1515/oncologie-2026-0225",
  "id": "cnh1e5kt5spzt",
  "issns": [
    "1765-2839",
    "1292-3818"
  ],
  "landing_url": "https://doi.org/10.1515/oncologie-2026-0225",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "R"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7172314961",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-01",
  "publisher": "De Gruyter",
  "ris": "https://research.draconitic.com/paper/cnh1e5kt5spzt.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T14:21:07Z",
      "native_id": "0cb4822313d84f8b8976c452c1b706b8",
      "source": "doaj",
      "url": "https://doi.org/10.1515/oncologie-2026-0225"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Can restoring major histocompatibility complex class I expression overcome immune evasion in brain cancers?",
  "title_text": "Can restoring major histocompatibility complex class I expression overcome immune evasion in brain cancers?",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T14:20:09Z",
  "url": "https://research.draconitic.com/paper/cnh1e5kt5spzt",
  "venue": "Oncologie",
  "versions": []
}